MM patients also present with recurrent somatic mutations, most commonly RAS pathway mutations such as NRAS, KRAS, and BRAF, which occur in around 40% of newly diagnosed MM and typically result in activation of MAPK signalling [44]. This evidence concerns the gene BRAF and Miyoshi myopathy.